A case of oncogenic osteomalacia detected by 111In-pentetreotide total body scan

Clinical and Experimental Rheumatology

Volumn 21, Issue 4, 2003, Pages 493-496

  Casari, Silvia ^a   Rossi, V ^a   Varenna, M ^a   Gasparini, M ^b   Parafioriti, A ^a   Failoni, S ^a   Sinigaglia, L ^a  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Hypophosphatemia; Octreotide; Oncogenic osteomalacia; Phosphatonin; Phosphaturia

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; MEDRONATE TECHNETIUM TC 99M; NONSTEROID ANTIINFLAMMATORY AGENT; PENTETREOTIDE IN 111; PHOSPHATE; PHOSPHORUS; SOMATOSTATIN RECEPTOR; STEROID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE BIOPSY; BONE PAIN; BONE SCINTISCANNING; CALCIUM BLOOD LEVEL; CASE REPORT; DISEASE SEVERITY; FEMALE; HEAD; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIMB; MAXILLA SINUS TUMOR; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMALACIA; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIODENSITOMETRY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOFT TISSUE; TUMOR LOCALIZATION; URINARY EXCRETION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADULT; BIOPSY, NEEDLE; BONE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEMANGIOPERICYTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MAXILLARY SINUS NEOPLASMS; OSTEOMALACIA; RISK ASSESSMENT; TECHNETIUM TC 99M PENTETATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0042700023     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. DREZNER MK: Tumor-induced rickets and osteomalacia. In FAVUS MJ (Ed.): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. New York, Raven Press 1996: 319-25.
2. HEWISON M: Tumor-induced osteomalacia. Curr Opin Rheumatol 1994; 6: 340-4.
3. REUBI JC, WASER B, LAISSUE JA, GEBBERS J: Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors in vitro identification. Cancer Res 1996; 56: 1922-31.
4. SLOOTER GD, MEARADJI A, BREEMAN WA et al.: Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. [Review] Br J Surg 2001; 88: 31-40.
5. 111In-pentetreotide. J Nucl Med 2001; 42: 1134-8.
6. RHEE Y-L, LEE J-D, SHIN K-H, LEE H-C, HUH K-B, LIM S-K: Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol 2001; 54: 551-4.
7. McCANCE RA: Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med 1947;16:33-46.
8. PRADER VA, ILLIG R, VEHLINGER E, STALDER G: Rachitis, infolge, knochen tumors. Helv Pediatr Acta 1959; 14: 554-65.
9. WEISS D, BAR RS, WEIDNER N, WENER M, LEE F: Oncogenic osteomalacia: Strange tumors in strange places. Post-graduate Med J 1985; 61: 349-55.
10. OGOSE A, HOTTA T, EMURA I et al.: Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol 2001; 30: 99-103.
11. JOHN MR, WICKERT H, ZAAR K et al.: A case of neuroendocrine oncogenic osteomalacia associated with a PHEX and fibroblast growth factor-23 expressing sinusidal malignant schwannoma. Bone 2001; 4: 393-402.
12. NELSON AE, ROBINSON BG, MASON RS: Oncogenic osteomalacia: Is there a new phosphate regulating hormone ? Clin Endocrinol 1996; 47: 635-42.
13. The HYP Consortium: A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nature Genet 1995; 11: 130-6.
14. HOLM IA, HUANG X, KUNKEL LM: Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am J Hum Genet 1997; 60: 790-7.
15. CAI Q, HODGSON SF, KAO PC et al.: Inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 1994; 330:1645-9.
16. NELSON AE, NAMKUNG HJ, PATAVA J et al.: Characteristics of tumor cell bioactivity in oncogenic osteomalacia. Mol Cell Endocrinol 1996; 124: 17-23.
17. BOWE AE, FINNEGAN R, JAN de BEUR SM et al.: FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Comm 2001; 284: 977-81.
18. KAWAI Y, MORIMOTO S, SAKAGUCHI K et al.: Oncogenic osteomalacia secondary to nasal tumor with decreased urinary excretion of cAMP. J Bone Miner Metab 2001; 19: 61-4.